This is interesting and a deal was made here so Teva has a 180 day exclusive. On one hand we have Teva in court with Merck over Singulair and on the other hand here, they get a deal. Teva is probably the most aggressive pharma company today with challenging patents.
Merck and Singulair – More Legal Battles Besides Teva With Patent Challenges
Both companies share one big common interest and that is the pursuit of Biosimilar Drugs – the Biotech side of generic drugs. This is still undecided in Congress as far as I know and there’s a lot of big players such as Amgen and many others in this lobbying effort in Washington.
Merck Purchases Insmed – Biosimilar Biotech Drug Company
“The terms "Biosimilar" or "Follow-on Biologic" refer to products that are marketed after expiration of patents, which are claimed to have similar properties to existing biologic products. Due to the complexity of biologics, a product can only be made that is similar, but not identical.” BD
NEW YORK, April 7 (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.TA) said on Wednesday it won U.S. approval for its generic versions of Merck & Co's (MRK.N) blockbuster blood-pressure drugs Cozaar and Hyzaar.
Teva, the world's biggest generic drugmaker, also said it will have 180 days to market the generics exclusively, an award generally given to companies that challenge patents first. Israel-based Teva (TEVA.O) said it was launching sales immediately.
An exclusivity period can allow generic companies a window of significant sales before rivals rush in and pricing freefalls.
UPDATE 1-Teva wins U.S. approval for generics of Merck drugs | Reuters
0 comments :
Post a Comment